openPR Logo
Press release

Non-Small Cell Lung Cancer (NSCLC) Global Market Report 2024 Global Market Analysis, Trends, Growth, Research And Forecast 2033

07-11-2024 12:29 PM CET | Health & Medicine

Press release from: The Business research company

Non-Small Cell Lung Cancer (NSCLC) Global Market

Non-Small Cell Lung Cancer (NSCLC) Global Market

The new report published by The Business Research Company, titled "Non-Small Cell Lung Cancer (NSCLC) Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the non-small cell lung cancer (nsclc) market size has grown rapidly in recent years. It will grow from $18.02 billion in 2023 to $20.1 billion in 2024 at a compound annual growth rate (CAGR) of 11.6%. The non-small cell lung cancer (nsclc) market size is expected to see rapid growth in the next few years. It will grow to $29.95 billion in 2028 at a compound annual growth rate (CAGR) of 10.5%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=13232&type=smp

Rising Tobacco Consumption Fuels Growth In The Non-Small Cell Lung Cancer (NSCLC) Market
The increasing rate of tobacco consumption is expected to propel the growth of the non-small cell lung cancer (NSCLC) market going forward. Tobacco consumption refers to the use of tobacco products by individuals, typically in the form of smoking, chewing, or snuffing, which introduces nicotine and other chemicals into the body. Tobacco smoke contains several carcinogens that can damage the DNA (deoxyribonucleic acid) in lung cells, leading to mutations and the uncontrolled growth of cancerous cells, including non-small-cell lung cancer (NSCLC). For instance, in July 2022, according to Statistics Canada, a Canada-based government agency, cigarette production increased by 5.8% compared to June 2021. The total number of cigarettes sold rose 1.3% from May 2022, reaching 1.4 billion in June 2022. Therefore, the increasing rate of tobacco consumption is driving the growth of the non-small cell lung cancer (NSCLC) market.

Rising Focus Of Companies To Embrace Advance Treatments To Gain Competitive Advantage
Major Companies operating in the non-small cell lung cancer (NSCLC) market are focused on developing multiple treatment options, such as monotherapy treatments, to gain a competitive edge. Monotherapy treatment is the use of a single drug or therapy to treat a medical disorder or condition, and it involves utilizing a single method or treatment approach rather than a combination of multiple interventions. For instance, in June 2022, Novartis AG, a Switzerland-based pharmaceutical company, received approval from the European Commission (EC), a Belgium-based governing body, for Tabrecta (capmatinib) for the treatment of adult patients with advanced non-small cell lung cancer with METex14 skipping. It offers a novel targeted therapeutic option for patients in Europe who have received prior treatment and have advanced non-small cell lung cancer (NSCLC) that has mutations that cause MET exon 14 (METex14) skipping. It is the most popular targeted treatment for advanced NSCLC and has modifications that cause METex14 skipping.

The non-small cell lung cancer (nsclc) market covered in this report is segmented -

1) By Type: Squamous Cell Carcinoma, Large Cell Carcinoma, Adenocarcinoma, Other Types
2) By Therapy: Radiotherapy, Laserthearpy, Photodynamic Therapy (PDT), Other Therapies
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Other Distribution Channels

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=13232&type=discount

Major companies operating in the non-small cell lung cancer (nsclc) market report are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Viatris Inc, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Hikma Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Zydus Lifesciences Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Almirall S.A., Clovis Oncology, Revolution Medicines

Contents of the report:
1. Executive Summary
2. Non-Small Cell Lung Cancer (NSCLC) Market Report Structure
3. Non-Small Cell Lung Cancer (NSCLC) Market Trends And Strategies
4. Non-Small Cell Lung Cancer (NSCLC) Market - Macro Economic Scenario
5. Non-Small Cell Lung Cancer (NSCLC) Market Size And Growth
…..
27. Non-Small Cell Lung Cancer (NSCLC) Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/non-small-cell-lung-cancer-nsclc-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Non-Small Cell Lung Cancer (NSCLC) Global Market Report 2024 Global Market Analysis, Trends, Growth, Research And Forecast 2033 here

News-ID: 3576430 • Views:

More Releases from The Business research company

Emerging Trends to Reshape the Global Fitness App Market: Revolutionizing Personal Training with AI Technology as a Key Influencer
Emerging Trends to Reshape the Global Fitness App Market: Revolutionizing Person …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Fitness App Market Size Valuation Forecast: What Will the Market Be Worth by 2025? The scale of the fitness app market has seen significant expansion in the past few years. It's projected to accelerate from a value of $14.66 billion in 2024 to a staggering $17.71 billion in 2025,
2025-2034 Enterprise Quantum Computing Market Evolution: Disruptions, Innovations, and Untapped Opportunities
2025-2034 Enterprise Quantum Computing Market Evolution: Disruptions, Innovation …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Is the Expected CAGR for the Enterprise Quantum Computing Market Through 2025? The market size of enterprise quantum computing has seen rapid expansion in the past few years. It is projected to escalate from $3.76 billion in 2024 to an impressive $4.78 billion in 2025, exhibiting a compound
Global Emotion Detection And Recognition Market Projected to Grow at 16.1% CAGR, Reaching $56.62 Billion by 2029
Global Emotion Detection And Recognition Market Projected to Grow at 16.1% CAGR, …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Will the Emotion Detection And Recognition Industry Market Size Be by 2025? The market size of emotion detection and recognition has seen a swift growth in the recent years. It is projected to expand from $27.64 billion in 2024 to $31.19 billion in 2025, with a Compound Annual
Global Digital Transformation Industry Outlook 2025-2029: Market Set to Cross $4315.18 Billion Milestone
Global Digital Transformation Industry Outlook 2025-2029: Market Set to Cross $4 …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. How Large Will the Digital Transformation Market Size By 2025? The rapid expansion of the digital transformation market in recent years has been notable. The market, which was valued at $1755.44 billion in 2024, is set to climb to a staggering $2105.59 billion in 2025, reflecting a compound annual

All 5 Releases


More Releases for NSCLC

NSCLC Patient Insights You Can't Afford to Ignore! A DelveInsight Case Study - H …
DelveInsight, a global leader in healthcare market intelligence and consulting, has successfully partnered with a top-tier biopharmaceutical company specializing in oncology to provide an advanced epidemiology forecasting analysis of Non-Small Cell Lung Cancer (NSCLC). This comprehensive study focused on biomarker-specific segmentation to support strategic drug development, identify target patient populations, and optimize market access planning across global markets. With the increasing complexity of NSCLC treatment, biomarker-driven therapies have emerged as a
Huateng Pharma Supplies Intermeidates of Pemetrexed Against NSCLC
Pemetrexed disodium is a drug successfully developed by Eli Lilly in the United States for the treatment of tumors, patent protection to January 2017. Pemetrexed disodium is a multi-targeted anti-folate agent with a core pyrrolopyrimidine moiety in its structure. It is a dual inhibitor of nucleotide synthase/dihydrofolate reductase, which inhibits cell replication by disrupting the normal process of folate-dependent metabolism in cells and simultaneously blocking three different enzyme targets critical
NSCLC Market Global Industry Analysis and Forecast Till 2027
Any type of epithelial lung cancer that isn't small cell lung cancer is referred to as NSCLC (SCLC). Squamous cell carcinoma, large cell carcinoma, and adenocarcinoma are the most common kinds of NSCLC, although there are several more types that are less common, and all types can occur in atypical histologic variants. Request Sample Copy of this Report: https://www.infinitybusinessinsights.com/request_sample.php?id=562904 Top Key Players Included in This Report: Merck KGa, Roche, Nlyte, Taxotere,
Targeted Drugs for NSCLC Market Size by 2025: QY Research
Global Targeted Drugs for NSCLC market report is first of its kind research report that covers the overview, summary, market dynamics, competitive analysis, and leading player’s various strategies to sustain in the global market. This report covers five top regions of the globe and countries within, which shows the status of regional development, consisting of market value, volume, size, and price data. Apart from this, the report also covers detail
"NSCLC - Market Outlook and Competitive Landscape Report 2015 – 2030 "
Report Snapshot: NSCLC is the most common form of lung cancer, accounting for approximately 85% of all types and subtypes of lung cancer. It grows and spreads more slowly than small cell lung cancer. Early stage disease is associated with uncommon specific symptoms; hence roughly ~50% to 73% of cases are not being diagnosed until the disease is at an advanced stage when the chances for cure or significant patient benefit
Global cancer immunotherapies Market 2016:Melanoma, Prostate cancer, NSCLC
Cancer Immunotherapies has brought an unprecedented change in the global cancer therapies market. Cancer immunotherapy can be defined as, the treatment that deploys the bodys immune system, by joining and boosting innate powers of the immune system to fight cancer. Over the past few years, cancer immunotherapies have generated new waves of optimism in the global oncology market, unveiling huge untapped potential for the innovators. After years of jostling over how